Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (141-150 of 259) with videos related to

Pageof 26
Sort By:
Journal of the National Cancer Institute|July 10, 2026
Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysisRoberto Buonaiuto, Martina Pagliuca, Alessandra Longobardi, et al.
Breast Cancer Research and Treatment|April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trialChristian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
Breast Cancer Research and Treatment|September 20, 2020
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
British Journal of Cancer|November 2, 2016
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patientsMatteo Lambertini, Ana Catarina Pinto, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Dissecting the heterogeneity of triple-negative breast cancerOtto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, et al.
Frontiers in Oncology|June 7, 2018
Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-AnalysisMárcio Debiasi, Carisi A Polanczyk, Patrícia Ziegelmann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapyEvandro de Azambuja, Lieveke Ameye, Marie Diaz, et al.
NPJ Breast Cancer|May 29, 2021
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancerTamar Zahavi, Mali Salmon-Divon, Roberto Salgado, et al.
JCO Global Oncology|April 6, 2021
OncoAlert Round Table Discussions: The Global COVID-19 ExperienceGilberto Morgan, Evandro de Azambuja, Kevin Punie, et al.
JAMA Oncology|June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical TrialRyan L Powles, David Redmond, Christos Sotiriou, et al.
Pageof 26

Showing results (141-150 of 259) with videos related to

Sort By:
Pageof 26
Journal of the National Cancer Institute|July 10, 2026
Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysisRoberto Buonaiuto, Martina Pagliuca, Alessandra Longobardi, et al.
Breast Cancer Research and Treatment|April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trialChristian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
Breast Cancer Research and Treatment|September 20, 2020
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
British Journal of Cancer|November 2, 2016
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patientsMatteo Lambertini, Ana Catarina Pinto, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Dissecting the heterogeneity of triple-negative breast cancerOtto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, et al.
Frontiers in Oncology|June 7, 2018
Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-AnalysisMárcio Debiasi, Carisi A Polanczyk, Patrícia Ziegelmann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapyEvandro de Azambuja, Lieveke Ameye, Marie Diaz, et al.
NPJ Breast Cancer|May 29, 2021
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancerTamar Zahavi, Mali Salmon-Divon, Roberto Salgado, et al.
JCO Global Oncology|April 6, 2021
OncoAlert Round Table Discussions: The Global COVID-19 ExperienceGilberto Morgan, Evandro de Azambuja, Kevin Punie, et al.
JAMA Oncology|June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical TrialRyan L Powles, David Redmond, Christos Sotiriou, et al.
Pageof 26